Kronos Bio, Inc.
KRONDelisted Jun 20, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001741830
Kronos Bio, Inc. was delisted on Jun 20, 2025; its insiders filed their last Form 4 on Jun 20, 2025; 47 institutions reported holding it in 13F filings for Q1 2025, worth $15.8M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Kronos Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Kronos Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Tanen David M | Director | 0Indirect | Jun 20, 2025 | 0 |
| Bischofberger Norbert W | Director, 10% Owner | 0Indirect | Jun 20, 2025 | 0 |
| Kazam Joshua A | Director | 0 | Jun 20, 2025 | 0 |
| Belldegrun Arie | Director | 0Indirect | Jun 20, 2025 | 0 |
| Yang Taiyin | Director | 0 | Jun 20, 2025 | 0 |
| Dansey Roger D | Director | – | Jun 20, 2025 | 0 |
| Ridloff Elena | Director | 0 | Jun 20, 2025 | 0 |
| Blunt Roshawn A. | Director | – | Jun 20, 2025 | 0 |
| Stultz Katherine V | Director | – | Jun 20, 2025 | 0 |
| Knobelman Deborah | President & Interim CEO | 0 | Jun 20, 2025 | 0 |
| Frisbee Allison | Chief Administrative Officer | 204,510 | Oct 15, 2024 | 0 |
| Lin Charles Y | Chief Scientific Officer | 234,603 | Oct 15, 2024 | 0 |
| Olek Elizabeth A | SR VP, CLINICAL SCIENCE | 193,275 | Feb 23, 2024 | 0 |
| Kosacz Barbara | COO & General Counsel | 928,966 | Jan 5, 2024 | 0 |
| DiMartino Jorge | Chief Medical Officer & VP | 315,246 | Jan 5, 2024 | 0 |
| Dinsmore Christopher | Chief Scientific Officer | 260,969 | Jan 5, 2024 | 0 |
| Al-Wakeel Yasir B. | Chief Financial Officer | 346,102 | Jul 7, 2023 | 0 |
| De Backer Marianne | Director | 14,083 | Jun 26, 2023 | 0 |
| Stampacchia Otello | Director | – | Jun 29, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 6, 2025 (view filing) | Jun 5 | 1 day | Knobelman DeborahPresident & Interim CEO | SSale | −24.8K | $0.87 | −$21.6K | −15.1%139.4K after | |
| Jul 1, 2024 (view filing) | Jun 27-28 | 4 days | Bischofberger Norbert WPRESIDENT & CEO | PPurchase | +615.5K | $1.20 | +$736.5K | +6.0%10.8M after | 2 lots |
| Jun 12, 2024 (view filing) | Jun 10-12 | 2 days | Bischofberger Norbert WPRESIDENT & CEO | PPurchase | +3.01M | $1.04 | +$3.12M | +68.8%7.38M after | 3 lots |
| Feb 23, 2024 (view filing) | Feb 21 | 2 days | Olek Elizabeth ASR VP, CLINICAL SCIENCE | SSale | −7.37K | $1.05 | −$7.74K | −3.7%193.3K after | |
| Feb 23, 2024 (view filing) | Feb 21 | 2 days | Lin Charles YSR VP, RESEARCH & DEVELOPMENT | SSale | −12.0K | $1.05 | −$12.6K | −4.9%234.6K after | |
| Feb 23, 2024 (view filing) | Feb 21 | 2 days | Frisbee AllisonSR VP, CORP OPERATIONS & LEGAL | SSale | −12.1K | $1.05 | −$12.7K | −5.6%204.5K after | |
| Jan 5, 2024 (view filing) | Jan 4 | 1 day | Dinsmore ChristopherChief Scientific Officer | SSale | −7.37K | $1.18 | −$8.69K | −2.7%261.0K after | |
| Jan 5, 2024 (view filing) | Jan 4 | 1 day | DiMartino JorgeChief Medical Officer & VP | SSale | −12.0K | $1.18 | −$14.2K | −3.7%315.2K after | |
| Jan 5, 2024 (view filing) | Jan 4 | 1 day | Kosacz BarbaraCOO & General Counsel | SSale | −10.7K | $1.18 | −$12.6K | −1.1%929.0K after | |
| Dec 13, 2023 (view filing) | Dec 12 | 1 day | Dinsmore ChristopherChief Scientific Officer | SSale | −10.0K | $1.31 | −$13.1K | −3.6%268.3K after | |
| Dec 13, 2023 (view filing) | Dec 12 | 1 day | DiMartino JorgeChief Medical Officer & VP | SSale | −17.4K | $1.31 | −$22.8K | −5.0%327.3K after | |
| Nov 17, 2023 (view filing) | Nov 15-17 | 2 days | Bischofberger Norbert WPresident & CEO | PPurchase | +1.73M | $0.8462 | +$1.46M | +213.8%2.54M after | 3 lots |
| Jul 7, 2023 (view filing) | Jul 6 | 1 day | Dinsmore ChristopherChief Scientific Officer | SSale | −6.63K | $1.75 | −$11.6K | −2.3%278.4K after | |
| Jul 7, 2023 (view filing) | Jul 6 | 1 day | DiMartino JorgeChief Medical Officer & VP | SSale | −10.8K | $1.75 | −$18.9K | −3.0%344.6K after | |
| Jul 7, 2023 (view filing) | Jul 6 | 1 day | Al-Wakeel Yasir B.Chief Financial Officer | SSale | −9.62K | $1.75 | −$16.8K | −2.7%346.1K after | |
| Feb 24, 2023 (view filing) | Feb 24 | Same day | Dinsmore ChristopherChief Scientific Officer | SSale | −6.29K | $1.74 | −$10.9K | −2.2%285.0K after | |
| Feb 24, 2023 (view filing) | Feb 24 | Same day | DiMartino JorgeChief Medical Officer & VP | SSale | −10.2K | $1.74 | −$17.7K | −2.8%355.4K after | |
| Feb 24, 2023 (view filing) | Feb 24 | Same day | Al-Wakeel Yasir B.Chief Financial Officer | SSale | −9.03K | $1.74 | −$15.7K | −2.5%355.7K after | |
| Dec 14, 2022 (view filing) | Dec 12 | 2 days | DiMartino JorgeChief Medical Officer & VP | SSale | −18.7K | $1.81 | −$33.8K | −7.8%219.5K after | |
| Dec 14, 2022 (view filing) | Dec 12 | 2 days | Dinsmore ChristopherChief Scientific Officer | SSale | −9.14K | $1.81 | −$16.5K | −5.3%162.9K after | |
| May 19, 2022 (view filing) | May 17-19 | 2 days | Bischofberger Norbert WPresident & CEO | PPurchase | +597.1K | $3.77 | +$2.25M | +281.0%809.6K after | 3 lots |
| Dec 15, 2021 (view filing) | Dec 13 | 2 days | Dinsmore ChristopherChief Scientific Officer | SSale | −11.4K | $12.37 | −$140.8K | −11.8%85.0K after | 2 lots |
| Dec 15, 2021 (view filing) | Dec 13 | 2 days | DiMartino JorgeChief Medical Officer & VP | SSale | −16.4K | $12.37 | −$202.8K | −12.2%117.5K after | 2 lots |
| Dec 8, 2021 (view filing) | Dec 6 | 2 days | Bischofberger Norbert WPresident & CEO | PPurchase | +14.4K | $12.09 | +$173.6K | +7.2%212.5K after | |
| Dec 2, 2021 (view filing) | Dec 1 | 1 day | De Backer MarianneDirector | PPurchase | +1.15K | $11.57 | +$13.3K | +71.9%2.75K after | |
| Oct 4, 2021 (view filing) | Oct 4 | Same day | Dinsmore ChristopherChief Scientific Officer | SSale | −9.19K | $20.81 | −$191.2K | −8.7%96.4K after | |
| Sep 9, 2021 (view filing) | Sep 7 | 2 days | Dinsmore ChristopherChief Scientific Officer | SSale | −9.19K | $21.91 | −$201.3K | −8.7%96.4K after | |
| Aug 24, 2021 (view filing) | Aug 20 | 4 days | De Backer MarianneDirector | PPurchase | +1.00K | $19.57 | +$19.6K | +166.7%1.60K after | 2 lots |
| Aug 3, 2021 (view filing) | Aug 2 | 1 day | Dinsmore ChristopherChief Scientific Officer | SSale | −9.19K | $20.59 | −$189.2K | −8.7%96.4K after |